Lessons from Recent Cardiovascular Outcome Trials of Type 2 Diabetes.

Kim,  Nam Hoon; Kim,  Sin Gon

doi:2017.18.1.7

J Korean Diabetes > Volume 18(1); 2017 > Article

Statement

The Journal of Korean Diabetes 2017;18(1):7-13.
DOI: https://doi.org/10.4093/jkd.2017.18.1.7 Published online April 3, 2017.

제2형 당뇨병 환자에서 진행된 대규모 심혈관 임상시험이 주는 교훈

김남훈, 김신곤

Lessons from Recent Cardiovascular Outcome Trials of Type 2 Diabetes.

Nam Hoon Kim, Sin Gon Kim

Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. k50367@korea.ac.kr

Abstract

Since the US Food and Drug Administration issued guidance requiring cardiovascular safety for all antidiabetic drugs in 2008 (US FDA industry guidance for licensing of antidiabetic drugs), the number of cardiovascular outcome trials in diabetes has remarkably increased. Cardiovascular outcome trial is considered a gold standard for establishing the cardiovascular safety of antidiabetic agents. However, there are possible limitations in information gained from cardiovascular outcome trials and other issues such as cost. In this review, we summarize recent cardiovascular outcome trials in type 2 diabetes and provide an overview of the implications and limitations of those trials.

Key Words: Cardiovascular disease, Diabetes mellitus, Randomized controlled trial, Type 2